Denna sida på svenska This page in English


Biomarkers are emerging as the most essential tool to boost efficiency in the field of precision diagnostics and of drug target discovery. Around 90% of new chemical compounds fail during clinical trials. Biomarkers have the potential to decrease this by identifying potential drug failures at an early stage, as well as providing clinicians with a predictive tool for patient stratification, using conventional drugs. Thus, the advent of biomarker pattern profiling, rather than reliance on a single target, are set to improve results, by allowing patient stratification, integrated with pre-clinical diagnosis and target discovery.

By integrating cutting-edge technologies, with clinical needs, we believe that we will be able to develop better predictors by integrating:

  • molecular profiling with clinical response
  • functional in vitro studies of biological mechanisms mediating tumour progression with drug response

Based on leading high-throughput technology development, the CREATE Health Center of Translational Cancer Research will have a major impact on the way diseases will be diagnosed, treated and managed.

At CREATE Health we are focusing on the following diseases: Pancreatic cancer, breast cancer, colon cancer, leukemia, lymphoma, neuroblastoma, prostate cancer, ovarial cancer, malignant melanoma and kidney cancer.